Victory Capital Management
LCTX icon

Victory Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Victory Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4K Sell
21,668
-5,253
-20% -$7.26K ﹤0.01% 2429
2026
Q1 		$42.5K Buy
26,921
+1,863
+7% +$3.14K ﹤0.01% 2324
2025
Q4 		$41.8K Sell
25,058
-1,129
-4% -$1.95K ﹤0.01% 2345
2025
Q3 		$44.3K Sell
26,187
-924
-3% -$1.09K ﹤0.01% 2353
2025
Q2 		$24.6K Sell
27,111
-296
-1% -$176 ﹤0.01% 2430
2025
Q1 		$12.4K Buy
27,407
+323
+1% +$189 ﹤0.01% 2447
2024
Q4 		$13.6K Buy
27,084
+3,219
+13% +$2.36K ﹤0.01% 2462
2024
Q3 		$21.6K Sell
23,865
-415
-2% -$385 ﹤0.01% 2436
2024
Q2 		$24.2K Sell
24,280
-390
-2% -$431 ﹤0.01% 2415
2024
Q1 		$36.5K Buy
24,670
+1,175
+5% +$1.33K ﹤0.01% 2398
2023
Q4 		$25.6K Buy
23,495
+4,265
+22% +$4.67K ﹤0.01% 2495
2023
Q3 		$22.7K Buy
19,230
+804
+4% +$1.09K ﹤0.01% 2441
2023
Q2 		$26K Sell
18,426
-428
-2% -$591 ﹤0.01% 2434
2023
Q1 		$28.3K Sell
18,854
-219
-1% -$306 ﹤0.01% 2486
2022
Q4 		$22.3K Sell
19,073
-7
-0% -$9 ﹤0.01% 2505
2022
Q3 		$22K Sell
19,080
-3,571
-16% -$5.24K ﹤0.01% 2622
2022
Q2 		$36K Buy
22,651
+241
+1% +$318 ﹤0.01% 2580
2022
Q1 		$27K Sell
22,410
-1,129
-5% -$1.75K ﹤0.01% 2632
2021
Q4 		$58K Sell
23,539
-574
-2% -$1.34K ﹤0.01% 2632
2021
Q3 		$61K Sell
24,113
-414
-2% -$1.06K ﹤0.01% 2672
2021
Q2 		$70K Buy
24,527
+1,133
+5% +$2.93K ﹤0.01% 2642
2021
Q1 		$55K Sell
23,394
-728
-3% -$1.75K ﹤0.01% 2662
2020
Q4 		$42K Buy
24,122
+1,233
+5% +$1.72K ﹤0.01% 2468
2020
Q3 		$21K Sell
22,889
-1,294
-5% -$1.14K ﹤0.01% 2433
2020
Q2 		$21K Sell
24,183
-727
-3% -$640 ﹤0.01% 2443
2020
Q1 		$21K Buy
+24,910
New +$24.8K ﹤0.01% 2825
2019
Q4 		– Sell
-25,867
Closed -$25K – 2966
2019
Q3 		$25K Buy
+25,867
New +$26.8K ﹤0.01% 2963

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Victory Capital Management's LCTX Position: Q2 2026 in Review

Victory Capital Management reduced its Lineage Cell Therapeutics (LCTX) stake by 20% in Q2 2026, selling an estimated $7.26K and leaving 21,668 shares worth $28.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2429.

Victory Capital Management first reported a position in LCTX in Q3 2019 and has held it in 27 quarters since. The position peaked at $70K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Victory Capital Management held 21,668 shares of Lineage Cell Therapeutics worth $28.4K as of Q2 2026.
  • Victory Capital Management sold 5,253 Lineage Cell Therapeutics shares in Q2 2026, an estimated $7.26K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2429 holding.
  • Victory Capital Management first reported a position in Lineage Cell Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Victory Capital Management's Lineage Cell Therapeutics position peaked at $70K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.